Detalhe da pesquisa
1.
Immune response to ART initiation in advanced HIV infection.
HIV Med
; 24(6): 716-726, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792544
2.
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Clin Infect Dis
; 59(3): 425-34, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24729492
3.
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
Infect Dis Ther
; 12(12): 2807-2817, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966701
4.
Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
Open Forum Infect Dis
; 9(3): ofac018, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35169590
5.
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
HIV Clin Trials
; 9(3): 152-63, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18547902
6.
Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
J Assoc Nurses AIDS Care
; 18(1 Suppl): S2-10, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17275719
7.
Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
J Assoc Nurses AIDS Care
; 18(1): 36-47, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17338984
8.
Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
AIDS
; 36(10): 1475-1476, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876710
9.
Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
HIV Clin Trials
; 11(3): 170-3, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736153
10.
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
BMC Infect Dis
; 5: 2, 2005 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-15647105
11.
Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
AIDS Rev
; 17(1): 21-36, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25472015
12.
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
AIDS
; 17(9): 1339-49, 2003 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-12799555
13.
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
AIDS
; 16(4): 579-88, 2002 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-11873001
14.
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
Clin Infect Dis
; 38(2): 263-70, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14699460
15.
Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
Clin Infect Dis
; 34(4): 535-42, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11797183
16.
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Clin Infect Dis
; 39(3): 411-8, 2004 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15307010
17.
Initial therapy for human immunodeficiency virus: broadening the options.
HIV Clin Trials
; 5(2): 99-111, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116286
18.
Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
HIV Clin Trials
; 3(5): 361-70, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12407485
19.
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
AIDS Res Hum Retroviruses
; 29(2): 250-5, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22738014
20.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
J Acquir Immune Defic Syndr
; 53(5): 614-8, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20134329